Akeso and Summit Therapeutics’ ivonescimab plus chemotherapy delivers a statistically significant overall survival benefit over a PD-1 inhibitor plus chemotherapy control in the Phase 3 HARMONi-6 trial for previously untreated advanced squamous non-small cell lung cancer, abemaciclib achieves the first-ever positive Phase 3 result in advanced dedifferentiated liposarcoma in the SARC041 trial, Eli Lilly and Verve Therapeutics’ VERVE-102 demonstrates up to 88 per cent PCSK9 reduction and up to 62 per cent LDL cholesterol reduction from a single infusion in the Phase 1b Heart-2 study, and ADC Therapeutics’ loncastuximab tesirine plus rituximab meets the primary endpoint in the Phase 3 LOTIS-5 confirmatory trial for relapsed or refractory diffuse large B-cell lymphoma, the most significant clinical trial results 5 June 2026 has to offer from across the pipeline.
This week was defined by the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, which delivered what leading oncologists have described as among the most consequential plenary data seen at the conference in years, spanning lung cancer, sarcoma, and pancreatic oncology. The squamous lung cancer result stands out as a historic moment for the field: it marks the first time any regimen has beaten an active PD-1 inhibitor plus chemotherapy control in a head-to-head Phase 3 survival analysis, while simultaneously representing the first China-originated investigational oncology therapy ever selected for the ASCO Plenary Session. Beyond oncology, a cardiovascular gene editing programme published in The New England Journal of Medicine is pointing toward a future in which a single infusion could replace a lifetime of daily lipid-lowering therapy. Here, Life Science Daily News brings you the most significant clinical trial results 5 June 2026.
Akeso and Summit Therapeutics’ Ivonescimab Beats PD-1 Inhibitor Plus Chemotherapy in Overall Survival in Phase 3 HARMONi-6 Trial for Squamous Non-Small Cell Lung Cancer
Akeso and Summit Therapeutics announced on 31 May 2026 positive overall survival results from the Phase 3 HARMONi-6 trial evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, in combination with chemotherapy versus tislelizumab plus chemotherapy as a first-line treatment for patients with previously untreated advanced squamous non-small cell lung cancer (sq-NSCLC). The results were presented in a Plenary Session at the ASCO Annual Meeting in Chicago and simultaneously published in The Lancet. Ivonescimab plus chemotherapy achieved a statistically significant and clinically meaningful improvement in overall survival (OS), with a median OS of 27.9 months compared with 23.7 months for the tislelizumab plus chemotherapy control arm, corresponding to a hazard ratio of 0.66 (95% CI 0.50–0.87; p=0.0017), a 34 per cent reduction in the risk of death. The OS benefit was consistent across prespecified subgroups, including patients with PD-L1 tumour proportion scores below 1 per cent, a population that has historically derived limited benefit from single-agent checkpoint inhibition. The 24-month OS rates were 64.7 per cent for ivonescimab plus chemotherapy versus 48.6 per cent for tislelizumab plus chemotherapy. The safety profile was manageable and consistent with previously reported data, with no new safety signals identified.
HARMONi-6 (NCT05840016) was a single-region, multi-centre Phase 3 study conducted in China and sponsored by Akeso, which randomised 532 patients with previously untreated stage IIIB, IIIC, or IV squamous NSCLC 1:1 to receive ivonescimab 20 mg/kg every three weeks or tislelizumab 200 mg every three weeks, each combined with paclitaxel and carboplatin for four cycles, followed by maintenance monotherapy. This result is the first time any regimen has demonstrated clinical superiority over an active PD-1 inhibitor plus chemotherapy control arm in a Phase 3 head-to-head survival analysis, a threshold that had until now resisted all challengers. The presentation also marked a historic milestone for Chinese oncology drug development: it was the first time a China-originated investigational oncology therapy has been selected for the ASCO Plenary Session in the conference’s 61-year history. Ivonescimab is developed by Akeso and is being commercialised outside of China and certain other territories by Summit Therapeutics. A separate BLA for ivonescimab in EGFR-mutated non-squamous NSCLC, based on the global HARMONi trial, is currently under FDA review with a PDUFA date of 14 November 2026; no regulatory submission has yet been made for the squamous NSCLC indication from HARMONi-6.
Abemaciclib Delivers the First Positive Phase 3 Trial Result in Advanced Dedifferentiated Liposarcoma in the SARC041 Study
Results from the Phase 3 SARC041 trial evaluating abemaciclib (Verzenio), an oral CDK4/6 inhibitor marketed by Eli Lilly, in patients with advanced dedifferentiated liposarcoma were presented in the ASCO 2026 Plenary Session on 31 May 2026 by lead investigator Mark A. Dickson, MD, of Memorial Sloan Kettering Cancer Center. SARC041 is an investigator-initiated study sponsored by the Sarcoma Alliance for Research through Collaboration. The trial met its primary endpoint with a statistically significant improvement in progression-free survival: median PFS was 9.7 months in the abemaciclib arm compared with 1.5 months in the placebo arm (hazard ratio 0.38; 90% CI 0.25–0.59; p<0.001), representing a 62 per cent reduction in the risk of progression or death. The six-month PFS rate was 60 per cent with abemaciclib versus 22 per cent with placebo; the twelve-month PFS rate was 39 per cent versus 13 per cent. A positive overall survival trend favoured abemaciclib, with a hazard ratio of 0.55 (95% CI 0.28–1.07; p=0.07), despite 85 per cent of placebo-arm patients crossing over to open-label abemaciclib upon progression. Dr Dickson described it as “the first positive Phase 3 clinical trial ever in dedifferentiated liposarcoma.”
SARC041 (NCT04967521) enrolled 108 patients with recurrent or metastatic dedifferentiated liposarcoma across nine academic sarcoma centres in the United States, randomised 1:1 to abemaciclib 200 mg orally twice daily or matching placebo. Eligible patients had documented disease progression within six months of study entry and could have received any number of prior systemic therapies. The biological rationale for the trial rested on CDK4 amplification, which is present in nearly all dedifferentiated liposarcomas and makes this tumour one of the most clearly defined CDK4-driven solid cancers in oncology. Dedifferentiated liposarcoma is a rare and aggressive soft-tissue sarcoma with approximately 3,000 cases per year in the United States. Available systemic options including doxorubicin, eribulin, and gemcitabine-based regimens have historically achieved median PFS of two to four months in this setting, leaving a significant unmet need. Abemaciclib is already approved by the FDA for hormone receptor-positive, HER2-negative early and advanced breast cancer; Lilly has not yet disclosed regulatory filing plans for the dedifferentiated liposarcoma indication.
Eli Lilly and Verve Therapeutics’ VERVE-102 Achieves Up to 88 Per Cent PCSK9 Reduction from a Single Infusion in Phase 1b Heart-2 Study
*This story was announced on 25 May 2026, within this edition’s coverage window but after the preceding roundup had closed. Given its clinical and scientific significance, Life Science Daily News is covering it here.*
Eli Lilly announced on 25 May 2026 positive interim results from the Phase 1b Heart-2 study evaluating VERVE-102, an investigational in vivo base editing medicine designed to permanently silence the PCSK9 gene in the liver following a single intravenous infusion. The trial is evaluating VERVE-102 in adults with heterozygous familial hypercholesterolaemia (HeFH) or premature coronary artery disease (CAD) who require additional lowering of LDL cholesterol despite maximally tolerated oral lipid-lowering therapy. The results were presented as a late-breaking oral presentation at the European Atherosclerosis Society Congress and simultaneously published in The New England Journal of Medicine. In this interim analysis of 35 participants across six dose cohorts (0.3–1.0 mg/kg), a single infusion of VERVE-102 produced dose-dependent mean reductions in circulating PCSK9 ranging from 51 to 88 per cent and corresponding mean reductions in LDL cholesterol ranging from 9 to 62 per cent, with the highest reductions observed at the 1.0 mg/kg dose. Durability of effect was observed for up to 18 months after treatment. No treatment-related serious adverse events and no dose-limiting toxicities were reported.
VERVE-102 is designed to mimic the protective effect of naturally occurring loss-of-function variants in PCSK9, which are associated with lifelong reductions in LDL cholesterol and significantly lower rates of cardiovascular events. The medicine uses Verve Therapeutics’ adenine base editing technology, which chemically converts a single DNA base at a specific site in the PCSK9 gene without creating double-strand DNA breaks. VERVE-102 is developed by Verve Therapeutics and was licensed to Eli Lilly under a collaboration agreement. The FDA has granted VERVE-102 Fast Track designation for the reduction of LDL cholesterol in patients with hyperlipidaemia and elevated long-term cardiovascular risk. Lilly plans to initiate a Phase 2 study by the end of 2026. The result adds to a growing body of evidence that in vivo gene editing therapies could offer a one-time alternative to the chronic daily medication regimens that currently underpin cardiovascular risk management, with adherence to existing lipid-lowering therapies remaining a persistent challenge for patients and clinicians alike.
ADC Therapeutics’ Loncastuximab Tesirine Plus Rituximab Meets Primary Endpoint in Phase 3 LOTIS-5 Confirmatory Trial for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics announced on 3 June 2026 topline data from the Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The trial is a randomised, open-label, two-arm, multicentre study comparing ZYNLONTA plus rituximab against rituximab, gemcitabine, and oxaliplatin (R-GemOx), the standard immunochemotherapy control, in patients with r/r DLBCL after one or more prior lines of systemic therapy. The trial met its primary endpoint of progression-free survival with statistical significance, with a median PFS of 6.1 months for ZYNLONTA plus rituximab versus 4.7 months for R-GemOx (hazard ratio 0.73; p=0.008). A higher complete response rate and longer duration of complete response were also observed in the ZYNLONTA plus rituximab arm. The key secondary efficacy endpoint of overall survival showed no detrimental effect (hazard ratio 0.96). Overall treatment-emergent adverse event rates were broadly similar between arms; haematologic adverse events were higher in the control arm, while infection, hepatotoxicity, and oedema or effusion rates were higher in the ZYNLONTA plus rituximab arm.
ZYNLONTA is a CD19-directed antibody-drug conjugate that received accelerated FDA approval in April 2021 for adults with relapsed or refractory large B-cell lymphoma after two or more prior lines of systemic therapy. LOTIS-5 (NCT04384484) is a confirmatory trial designed to fulfil post-marketing requirements and support a supplemental Biologics License Application (sBLA). ADC Therapeutics has stated it intends to conduct a pre-sBLA meeting with the FDA in August 2026 and is targeting an sBLA submission in the fourth quarter of 2026. Diffuse large B-cell lymphoma is the most common form of non-Hodgkin lymphoma, accounting for approximately 25 per cent of all cases. Despite advances in front-line chemoimmunotherapy, a significant proportion of patients relapse or develop refractory disease and require further lines of therapy. The confirmatory Phase 3 data from LOTIS-5 strengthen the evidence base for the CD19-targeting ADC approach in this setting and support the potential for expanded use of loncastuximab tesirine in the treatment landscape for aggressive B-cell malignancies.
Looking Ahead
This week’s clinical trial results 5 June 2026 reflect a pipeline operating at an exceptional level of ambition and output, with ASCO 2026 delivering practice-changing evidence across some of the most difficult treatment landscapes in oncology. The ivonescimab OS result in squamous lung cancer redraws the competitive map for first-line therapy and sets a new benchmark for what is achievable in a head-to-head immunotherapy comparison, even as the single-region nature of the HARMONi-6 study means global regulatory filings in this indication remain a step away. The abemaciclib data in dedifferentiated liposarcoma offer, for the first time, a molecularly rational and statistically robust treatment option in a sarcoma subtype where systemic therapy has historically offered little. The single-dose base editing result in familial hypercholesterolaemia represents a meaningful step toward a future where cardiovascular risk management could begin and end with a single infusion. And the LOTIS-5 confirmatory result secures an important regulatory milestone for an already-approved ADC in a disease that continues to claim tens of thousands of lives each year. Life Science Daily News will continue to bring you accurate, timely coverage of the clinical trial results 5 June 2026 that matter most across the global life sciences pipeline.
This clinical trials roundup is produced by the Life Science Daily News editorial team. All stories are selected and written independently.
